Open AccessKey differences between anti-PD-1/PD-L1 inhibitors
Author(s) -
Natalia V. Zhukova,
Р. В. Орлова,
Ekaterina Kaledina,
Poliymushina,
Анна Малкова,
Natalia P. Beliak
Publication year - 2022
Publication title -
medicinskij sovet
Language(s) - Uncategorized
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2022-16-9-22-28
Subject(s) - pembrolizumab , atezolizumab , nivolumab , avelumab , durvalumab , discontinuation , toxicity , medicine , drug , immunotherapy , pharmacology , oncology , cancer